Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: heterogeneity of splice variants and induction by TGF-beta.
Localization of tenascin-C in vivo and cell culture experiments in vitro have provided evidence for stromal production of tenascin-C in malignant tumors of a variety of organs. Here we raised the question of whether the mesenchymal stroma in the case of endometrial adenocarcinoma is the unique source of tenascin-C. Therefore, the expression of tenascin-C mRNA by human endometrial adenocarcinoma cells and endometrial stroma cells was investigated. Several preparations of endometrial stroma cells produced tenascin-C mRNA. Using a serum-free defined cell culture medium, production of tenascin-C mRNA could be increased by adding either serum or 20 ng TGF-beta/mL to the cell culture medium. Reverse transcriptase polymerase chain reaction analysis revealed that five out of six endometrial adenocarcinoma cell lines produced tenascin-C mRNA. Northern blot experiments and ribonuclease protection assays provided evidence that the number of copies of tenascin-C mRNA was small. Analysis of expressed splice variants by reverse transcriptase polymerase chain reaction analysis revealed the abundance of one major splice variant that lacked all potential alternatively spliced fibronectin type-III-like repeats. Regarding larger splice variants, all fragment sizes that could theoretically originate from seven alternatively spliced fibronectin type-III-like repeats were observed. Evaluating relative signal intensities, the splice variants containing a single fibronectin type-III-like repeat and the variant possessing all but one alternatively spliced repeats were most frequent. In summary, evidence is provided that tenascin-C can originate from both tissue compartments of the human endometrium stroma and (tumor) epithelium. Splice variant analysis revealed a high number of splice variants and a relative high proportion of variants that have so far been regarded as minor constituents of expressed tenascin-C.
Vollmer
G
G
Institut für Biochemische Endokrinologie, Medizinische Universität zu Lübeck, Germany. vollmer@imm.mu-luebeck.de
Tan
M I
MI
Wünsche
W
W
Frank
K
K
D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism*; D017398:Alternative Splicing / Q000187:drug effects*; D000818:Animals; D015152:Blotting, Northern; D002417:Cattle; D017931:DNA Primers; D016889:Endometrial Neoplasms / Q000235:genetics / Q000378:metabolism*; D004717:Endometrium / Q000166:cytology* / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000502:physiology; D006801:Humans; D016133:Polymerase Chain Reaction; D012260:Ribonucleases; D017154:Stromal Cells / Q000378:metabolism; D019063:Tenascin / Q000096:biosynthesis* / Q000187:drug effects / Q000235:genetics*; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D017931:DNA Primers; D019063:Tenascin; D016212:Transforming Growth Factor beta; D012260:Ribonucleases